Download Files:
Products Details
Product Description
– K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity[1].
Web ID
– HY-15779
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C18H24N2O3S
Citations
– Am J Cancer Res. 2019 Mar 1;9(3):546-561.|Biochem Biophys Res Commun. 2017 Nov 4;493(1):286-290. |Channels. 2020 Dec;14(1):216-230.|Exp Mol Pathol. 2016 Feb;100(1):51-8. |Sci China Life Sci. 2021 May 27;1-21.|Biochem Biophys Res Commun. 2021 Sep 28;580:1-6.
References
– [1]Liu K, et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471.
CAS Number
– 1309444-75-4
Molecular Weight
– 348.46
SMILES
– O=C(N(CCN)C/1=O)SC1=C/CCC2=CC=C(OCCCC)C=C2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;SphK
Isoform
– SphK2
Pathway
– Apoptosis;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
